Posting of Annual Report and Notice of AGM

Destiny Pharma PLC

26 April 2023

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Posting of Annual Report and Accounts, and Notice of AGM

Brighton, United Kingdom - 26 April 2023 - Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that the following documents are now available on the Company's website at www.destinypharma.com

•    Annual Report and Accounts of the Company for the year ended 31 December 2022

•    Notice of the 2023 Annual General Meeting ("AGM") and details for voting by proxy, which is to be held at 11.00 a.m. on 25 May 2023 at the offices of finnCap Ltd, One Bartholomew Close, London, EC1A 7BL

Printed copies of both documents will be posted to shareholders today.

In order to ensure that shareholders are able to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company platform. However, please note that shareholders will not be able to vote online at the AGM via the platform and are therefore requested to submit their votes via proxy, as early as possible. Shareholders are invited to submit any questions for the Board to consider. Questions can be pre submitted ahead of the AGM via the Investor Meet Company Platform up until 9 a.m. the day before the AGM or submitted at any time during the AGM itself. 

Shareholders that wish to attend the AGM remotely should register for the event in advance by using the following link: https://www.investormeetcompany.com/destiny-pharma-plc/register-investor

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
[phone]
[e-mail]

Optimum Strategic Communications
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper
[phone]
[e-mail]

finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
[phone]

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

MC Services AG
Anne Hennecke / Andreas Burckhardt
[phone]

Stern IR - US

Janhavi Mohite

[phone]

[e-mail]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV^TM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the Company, please visit www.destinypharma.com

 

END